5-alpha reductase type 1 Inhibitors
1 drugsAbout 5-alpha reductase type 1
5-alpha reductase type 1 (5αR1) converts testosterone to dihydrotestosterone (DHT), a potent androgen, and is one of two isoforms of this enzyme. Its distinct tissue distribution and enzymatic properties make it a target for drug development, modulating androgen-related pathways.
The rationale for targeting 5αR1 stems from its involvement in androgen metabolism. Currently, there is no genetic evidence available linking 5αR1 to specific diseases, but understanding its contribution to androgen metabolism is crucial.
There is one FDA-approved drug, AVODART, a small molecule targeting 5αR1, with applications categorized as 'other'. WAYLIS THERAP is the only company with an approved drug for this target.
Top 5-alpha reductase type 1 Drugs
WAYLIS THERAP is the only company with an approved drug targeting 5-alpha reductase type 1.
Low competition suggests an opportunity for new entrants, but also indicates potential market risk.
5-alpha reductase type 1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets 5-alpha reductase type 1, using small molecule modality.
Explore alternative modalities like antibodies to differentiate from existing therapies.
5-alpha reductase type 1 Clinical Trials 53 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on 5-alpha reductase type 1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 19 | 16 | 2 | 1 | 89% |
| Phase 2 | 16 | 9 | 5 | 2 | 64% |
| Phase 3 | 8 | 6 | 0 | 2 | 100% |
| Phase 4 | 10 | 8 | 1 | 1 | 89% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
5-alpha reductase type 1 Drug Approval Timeline (2001 - 2001)
The first and most recent drug approval for this target was AVODART in 2001.
The lack of recent approvals indicates a potentially saturated market or challenges in drug development.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 31 (9 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on 5-alpha reductase type 1. A trial counts if an approved drug acting on 5-alpha reductase type 1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.